Vitruvias Therapeutics pulls nationwide thyroid tablet lot over excess potency

Vitruvias Therapeutics announced a voluntary recall of Lot 504950 of its 30 mg Thyroid Tablets, USP, after laboratory analysis indicated the tablets might be more potent than intended. The U.S. Food and Drug Administration posted the recall notice, warning that the excess potency could trigger hyperthyroidism with symptoms such as weight loss, heat intolerance, fatigue, nervousness, high blood pressure and heart rhythm disturbances, particularly dangerous for seniors, pregnant women and infants.

The affected lot, bearing NDC 69680-166-00 and expiring on Sept. 30, 2026, was distributed nationwide through the company's direct accounts between Jan. 31, 2025 and Sept. 30, 2025, with 3,655 units released and 1,955 units sold. No adverse events have been reported to date. Vitruvias is notifying wholesalers to halt sales and to destroy the product, while urging patients to continue their regimen only under medical guidance and to seek a replacement prescription if needed. The recall is being conducted with FDA awareness.